JP2021521817A5 - - Google Patents

Info

Publication number
JP2021521817A5
JP2021521817A5 JP2020559369A JP2020559369A JP2021521817A5 JP 2021521817 A5 JP2021521817 A5 JP 2021521817A5 JP 2020559369 A JP2020559369 A JP 2020559369A JP 2020559369 A JP2020559369 A JP 2020559369A JP 2021521817 A5 JP2021521817 A5 JP 2021521817A5
Authority
JP
Japan
Prior art keywords
region
fusion protein
cells
immunoglobulin
cancer
Prior art date
Application number
JP2020559369A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521817A (ja
JPWO2019209078A5 (https=
JP7485368B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2019/005096 external-priority patent/WO2019209078A1/ko
Publication of JP2021521817A publication Critical patent/JP2021521817A/ja
Publication of JPWO2019209078A5 publication Critical patent/JPWO2019209078A5/ja
Publication of JP2021521817A5 publication Critical patent/JP2021521817A5/ja
Application granted granted Critical
Publication of JP7485368B2 publication Critical patent/JP7485368B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020559369A 2018-04-26 2019-04-26 新規な融合タンパク質およびこれを含む癌の予防または治療用薬学的組成物 Active JP7485368B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2018-0048343 2018-04-26
KR20180048343 2018-04-26
PCT/KR2019/005096 WO2019209078A1 (ko) 2018-04-26 2019-04-26 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물

Publications (4)

Publication Number Publication Date
JP2021521817A JP2021521817A (ja) 2021-08-30
JPWO2019209078A5 JPWO2019209078A5 (https=) 2022-04-19
JP2021521817A5 true JP2021521817A5 (https=) 2022-04-19
JP7485368B2 JP7485368B2 (ja) 2024-05-16

Family

ID=68293649

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020559369A Active JP7485368B2 (ja) 2018-04-26 2019-04-26 新規な融合タンパク質およびこれを含む癌の予防または治療用薬学的組成物

Country Status (6)

Country Link
US (1) US11820801B2 (https=)
EP (1) EP3792276A4 (https=)
JP (1) JP7485368B2 (https=)
KR (3) KR102194644B1 (https=)
CN (1) CN112041333B (https=)
WO (1) WO2019209078A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210347849A1 (en) * 2018-07-24 2021-11-11 Good T Cells, Inc. Composition for Preventing or Treating Immune-Related Diseases
CN113811330A (zh) * 2019-03-20 2021-12-17 古德T细胞有限公司 预防或治疗脑和神经系统疾病的组合物
AU2020380072B2 (en) * 2019-11-08 2025-11-27 Good T Cells, Inc. Epitope of regulatory T cell surface antigen, and antibody specifically binding thereto
CN111285936A (zh) * 2020-03-11 2020-06-16 北京双赢科创生物科技有限公司 靶向肿瘤的酸性敏感纳米肽段及其应用
KR20250036703A (ko) * 2023-09-06 2025-03-14 주식회사 굳티셀 친화도 성숙이 이루어진 신규 항체

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
JP2008504008A (ja) * 2003-12-31 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
WO2007013671A2 (en) * 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
CN105131127B (zh) 2007-05-30 2018-09-07 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
US8933197B2 (en) * 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
CN101891823B (zh) * 2010-06-11 2012-10-03 北京东方百泰生物科技有限公司 一种Exendin-4及其类似物融合蛋白
KR101847523B1 (ko) 2011-01-24 2018-05-28 연세대학교 산학협력단 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도
RS61391B1 (sr) 2012-06-08 2021-02-26 Alkermes Pharma Ireland Ltd Ligandi modifikovani primenom cirkularnog permutiranja kao agonisti i antagonisti
EP3456734B1 (en) 2012-10-04 2022-01-05 Research Development Foundation Serine protease molecules and therapies
WO2015016616A1 (ko) * 2013-07-30 2015-02-05 연세대학교 산학협력단 삭사틸린-Ｆｃ 융합 단백질 및 이의 용도
US20210347849A1 (en) 2018-07-24 2021-11-11 Good T Cells, Inc. Composition for Preventing or Treating Immune-Related Diseases

Similar Documents

Publication Publication Date Title
JP7485368B2 (ja) 新規な融合タンパク質およびこれを含む癌の予防または治療用薬学的組成物
JP2021521817A5 (https=)
JPH04501719A (ja) ポリペプチド
CN116096897A (zh) 抗4-1bb-抗pd-l1双特异性抗体、其药物组合物及用途
EA029300B1 (ru) Антитело к связанному с мембраной человеческому карциноэмбриональному антигену, его получение и применение
KR102652664B1 (ko) 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체
WO2019091449A1 (zh) Cd96抗体、其抗原结合片段及医药用途
CN112794911B (zh) 人源化抗叶酸受体1抗体及其应用
EP4467567A1 (en) Anti-cd70 nanoantibody and use thereof
KR20180117067A (ko) Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도
CN110028584A (zh) 针对egfr蛋白和met蛋白的双特异性抗体
KR20250101988A (ko) 면역체크포인트 억제제 저항성 암의 예방, 개선 또는 치료용 조성물
CN121175410A (zh) TrkA抗体及其用途
CN101627053A (zh) 泛细胞表面受体特异的治疗剂
CN110799211B (zh) 特异性识别丛蛋白-信号素-整合素结构域的抗ron单克隆抗体的药物呈递作用及其在肿瘤治疗中的应用
JP2007527232A (ja) Ｎｏｇｏ−ａ結合分子およびその医薬的使用
JPWO2019209078A5 (https=)
CN115947855B (zh) 抗cd24抗体的制备及其用途
EP4265269A1 (en) Use of taci protein
KR20130057959A (ko) 항 ｈｅｒ2 단일클론항체와 ｉｌ-2를 포함하는 융합 단일클론 항체 및 이를 포함하는 암치료용 조성물
TW202602928A (zh) 程序性死亡配體1(pd-l1)嵌合抗原受體及其應用
WO2025099324A1 (en) Antibodies against cd44
WO2025119330A1 (zh) 氨基酸接头结合分子及其用途
CN118307671A (zh) Pd-1结合分子及其用途
CN117186222A (zh) Pd-l1结合分子及其用途